| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/26/2004 | EP1420815A2 Beta-amyloid-analogue - t-cell epitop vaccine |
| 05/26/2004 | EP1420810A1 Modulation of leukocyte-endothelial interactions following ischemia |
| 05/26/2004 | EP1420801A1 Use of fucans in the treatment of adhesions, arthritis and psoriasis |
| 05/26/2004 | EP1420800A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity |
| 05/26/2004 | EP1420799A2 Use of atazanavir in hiv therapy |
| 05/26/2004 | EP1420797A1 Dermal therapy using phosphate derivatives of electron transfer agents |
| 05/26/2004 | EP1420795A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness |
| 05/26/2004 | EP1420792A2 Products and drug delivery vehicles |
| 05/26/2004 | EP1420791A1 Use of compounds for treating conditions resulting from injury to the corneal nerve after lasik and other ocular surgeries or trauma |
| 05/26/2004 | EP1420790A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 05/26/2004 | EP1420778A2 Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock |
| 05/26/2004 | EP1420774A1 Preparation and diabetic use of gibberellins |
| 05/26/2004 | EP1420772A2 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases |
| 05/26/2004 | EP1420769A2 Lipid profile modulation with steroids |
| 05/26/2004 | EP1420760A2 Aerosolized decongestants for the treatment of sinusitis |
| 05/26/2004 | EP1420745A2 Use of r-nsaid compounds for anti-hiv treatment |
| 05/26/2004 | EP1420716A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues |
| 05/26/2004 | EP1420645A1 Multivesicular emulsion topical delivery systems |
| 05/26/2004 | EP1328269B1 Association of a cb1 receptor antagonist and sibutramin for treating obesity |
| 05/26/2004 | EP1206258B1 Compositions containing esters for treating parasitic infestations of organisms |
| 05/26/2004 | EP1187605A4 Non-malignant disease treatment with ras antagonists |
| 05/26/2004 | EP1165074B1 Viral treatment |
| 05/26/2004 | EP1161226B1 Phosphocholine linked prodrug derivatives |
| 05/26/2004 | EP1104475B1 C-myc is activated by beta-catenin and tcf-4 |
| 05/26/2004 | EP1083927B1 HUMAN MINOR VAULT PROTEIN p193 |
| 05/26/2004 | EP1059941B1 Pharmaceutical compositions and their use |
| 05/26/2004 | EP0969851B1 Immunomodulatory complex and use thereof in helicobacter diseases |
| 05/26/2004 | EP0929300B1 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 05/26/2004 | EP0786253B1 Antitumor composition comprising ascorbic acid and metal complexes of (na)phthalocyanines |
| 05/26/2004 | EP0778768B1 Formulations and methods for providing prolonged local anesthesia |
| 05/26/2004 | EP0740650B1 Codrugs as a method of controlled drug delivery |
| 05/26/2004 | CN1500089A Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain |
| 05/26/2004 | CN1500082A Cyano-5ubstituted dihydropyrimidine compounds and their use to treat diseases |
| 05/26/2004 | CN1500078A Aryl oxime-piperazines useful as CCR5 antagonists |
| 05/26/2004 | CN1499983A Remedies for infact chronic arthritis-relating diseases |
| 05/26/2004 | CN1499982A Use of Il-18 inhibitors for treatment and/or prevention of heart disease |
| 05/26/2004 | CN1499981A Combined use of factor VII polypeptides and factor IX polypeptides |
| 05/26/2004 | CN1499968A Method of treatment of dopamine-related dysfuction |
| 05/26/2004 | CN1499936A Mixtures of fructose and lactose as low-calorie bulk sweetener with reduced glycemic index |
| 05/26/2004 | CN1499927A Erythropoietin ameliorates chemotheapy-induced toxicity in vivo |
| 05/26/2004 | CN1498659A Nutritious supplementing agent contg. a-glucosidase inhibitor and a-amylase inhibitor |
| 05/26/2004 | CN1150943C Immobilized activity stabilized LHRH-antagonist complexes, method for prodn. thereof |
| 05/26/2004 | CN1150904C Pharmaceutical compositions for oral administration of molecular iodine |
| 05/26/2004 | CN1150897C Injectable composition of non-steroidal anti-inflammatory drugs |
| 05/25/2004 | US6740738 Antibodies binding to polypeptides encoded by the genes |
| 05/25/2004 | US6740674 Administering formulation comprising proteasome inhibitor in carrier for therapy of dry eye disorder |
| 05/25/2004 | US6740672 Administering alosetron, tropisetron, ondansetron, granisetron and/or bemesetron |
| 05/25/2004 | US6740666 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
| 05/25/2004 | US6740665 Tyrosine kinase inhibitors and methods of using the same |
| 05/25/2004 | US6740664 A new class of quinolone antibiotic (e.g., moxifloxacin) is useful for treating otic, opthalmic or nasal infections attributed to a microbacterium species selected from microbacterium otitidis or microbacterium alconae |
| 05/25/2004 | US6740660 For amelioration of erectile dysfunction in a mammal without causing substantial intolerable adverse side effects to mammal |
| 05/25/2004 | US6740659 Treatment of dyskinesia |
| 05/25/2004 | US6740655 3',5'-cyclic nucleotide phosphodiesterase 4-specific inhibitors reduce eosinophil influx to the lungs; side effect reduction; antiinflammatory agent; antiallergens; respiratory system disorders, especially asthma |
| 05/25/2004 | US6740648 Using a vasopressin antagonist such as conivaptan |
| 05/25/2004 | US6740646 Bioavailable prodrugs of androgenic steroids and related method |
| 05/25/2004 | US6740636 Non-peptide CCR1 receptor antagonists in combination with cyclosporin A for the treatment of heart transplant rejection |
| 05/25/2004 | US6740635 Aids therapy, respiratory syncytial virus |
| 05/25/2004 | US6740327 Use for cosmetic and dermatological indications, reducing and soothing mucosa and skin erythema, inflammation or reaction caused by internal or external factors, wound healing, etc. |
| 05/25/2004 | US6740321 Administering to treat hypothyroidism or hyperthyroidism |
| 05/25/2004 | US6740309 Delivery of compounds for the treatment of migraine through an inhalation route |
| 05/25/2004 | US6740308 Composition comprising condensation aerosol formed by volatilizing antihistamine under conditions effective to produce heated vapor and condensing to form condensation aerosol particles having less than 5% degradation products |
| 05/25/2004 | US6740307 Delivery of β-blockers through an inhalation route |
| 05/25/2004 | US6740306 Imidazotriazinone-containing compositions for nasal administration |
| 05/25/2004 | CA2278782C Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders |
| 05/25/2004 | CA2140468C Percutaneous administration tape preparation |
| 05/25/2004 | CA2046337C Improved transdermal system for the administration of pharmacological compounds under ph-controlled conditions |
| 05/21/2004 | WO2004041809A2 Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands |
| 05/21/2004 | WO2004041309A1 Drugs comprising combination of elastase inhibitor with blood coagulation system and/or fibrinolysis system enzyme inhibitor |
| 05/21/2004 | WO2004041308A1 Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
| 05/21/2004 | WO2004041301A1 Antidiuretics |
| 05/21/2004 | WO2004041278A1 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 05/21/2004 | WO2004041272A2 Use of serotonin receptor antagonists for the treatment of sleep apnea |
| 05/21/2004 | WO2004041257A2 Novel nutraceutical compositions comprising epigallocatechin gallate |
| 05/21/2004 | WO2004041250A2 Nanoparticulate fibrate formulations |
| 05/21/2004 | WO2004041193A2 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5 |
| 05/21/2004 | WO2004041191A2 Methods for the treatment, prevention and management of macular degeneration |
| 05/21/2004 | WO2004041185A2 Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells |
| 05/21/2004 | WO2004041176A2 The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus |
| 05/21/2004 | WO2004041169A2 Modulation of cell fates and activities by phthalazine diones |
| 05/21/2004 | WO2004041162A2 Inhibitors of akt activity |
| 05/21/2004 | WO2004041159A2 Composition and method for enhancing immune response of swine |
| 05/21/2004 | WO2004041158A2 Rifalazil compositions and therapeutic regimens |
| 05/21/2004 | WO2004041154A2 Abuse-resistant opioid dosage form |
| 05/21/2004 | WO2004041151A2 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 05/21/2004 | WO2004041118A2 Therapeutic compositions for drug delivery to and through covering epithelia |
| 05/21/2004 | WO2004041106A1 Methods and systems for enabling and stabilizing tooth movement |
| 05/21/2004 | WO2004041067A2 Prevention and treatment of synucleinopathic disease |
| 05/21/2004 | WO2004027020A9 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 05/21/2004 | WO2004022709A3 Epitope sequences |
| 05/21/2004 | WO2004016244A3 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 05/21/2004 | WO2004016243A3 Methods of administering and enhancing absorption of pharmaceutical agents |
| 05/21/2004 | WO2004014413A8 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 05/21/2004 | WO2004014222A3 Diagnosis and treatment of tuberous sclerosis |
| 05/21/2004 | WO2004011029A3 Pharmaceutical compositions for penis enlargement |
| 05/21/2004 | WO2004005476A3 Nucleic acid compositions for stimulating immune responses |
| 05/21/2004 | WO2004000817A3 Benzimidazole compounds and their use as estrogen agonists/antagonists |
| 05/21/2004 | WO2004000311A3 Pharmaceutical composition comprising calcium channel blockers for the treatment of pain |
| 05/21/2004 | WO2003093322A3 Carrageenan based antimicrobial compositions |
| 05/21/2004 | WO2003088900A3 Solid forms of salts with tyrosine kinase activity |
| 05/21/2004 | WO2003085110A3 Oligomeric compounds for the modulation hif-1alpha expression |